DailyStocks Stock Article Search

https://www.zacks.com/stock/news/2219647/merck-mrk-q4-earnings-taking-a-look-at-key-metrics-versus-estimates?cid=CS-ZC-FT-fundamental_analysis|nfm-2219647 Feb 01, 2024 - The headline numbers for Merck (MRK) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. 0

https://www.zacks.com/stock/news/2220267/stock-market-news-for-feb-2-2024?cid=CS-ZC-FT-market_news-2220267 Feb 02, 2024 - U.S. stocks closed higher on Thursday as they tried to recover from a massive selloff in the previous session after the Federal Reserve held interest rates steady but also said that a rate cut in March is unlikely. 0

https://www.zacks.com/stock/news/2221915/merck-mrk-unit-to-buy-elanco-s-aqua-business-for-1-3b?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2221915 Feb 06, 2024 - Merck's (MRK) Animal Health unit is set to strengthen its position with the acquisition of Elanco Animal Health's aqua business for $1.3 billion. The transaction is expected to close by mid-2024. 0

https://www.zacks.com/stock/news/2224190/pharma-stock-roundup-azn-lly-s-q4-earnings-nvo-nvs-mrk-s-m-a-deals?cid=CS-ZC-FT-analyst_blog|stock_roundup-2224190 Feb 09, 2024 - Eli Lilly (LLY) and AstraZeneca (AZN) announce fourth-quarter results. Novo Nordisk (NVO), Merck (MRK) and Novartis (NVS) make M&A announcements. 0

https://www.zacks.com/stock/news/2227548/corcept-cort-q4-earnings-beat-estimates-korlym-sales-grow?cid=CS-ZC-FT-analyst_blog|earnings_article-2227548 Feb 16, 2024 - Corcept (CORT) beats on both earnings and sales in the fourth quarter. The company also reiterates its previously provided guidance for 2024. 0

https://www.zacks.com/stock/news/2228028/moderna-mrna-gears-up-for-q4-earnings-will-it-top-estimates?cid=CS-ZC-FT-analyst_blog|earnings_preview-2228028 Feb 19, 2024 - Investors' focus will likely be on updates on Moderna's (MRNA) pipeline, especially its late-stage pipeline candidates, when it reports fourth-quarter earnings. 0

https://www.zacks.com/commentary/2228528/top-research-reports-for-merck-servicenow-blackstone?cid=CS-ZC-FT-research_daily-2228528 Feb 20, 2024 - Today's Research Daily features new research reports on 16 major stocks, including Merck & Co., Inc. (MRK), ServiceNow, Inc. (NOW) and Blackstone Inc. (BX). 0

https://www.zacks.com/stock/news/2234897/merck-mrk-stock-falls-amid-market-uptick-what-investors-need-to-know?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6-2234897 Mar 01, 2024 - In the most recent trading session, Merck (MRK) closed at $126.96, indicating a -0.15% shift from the previous trading day. 0

https://www.zacks.com/commentary/2243512/top-research-reports-for-jpmorgan-chase-merck-sap?cid=CS-ZC-FT-research_daily-2243512 Mar 20, 2024 - Today's Research Daily features new research reports on 16 major stocks, including JPMorgan Chase & Co. (JPM), Merck & Co., Inc. (MRK) and SAP SE (SAP). 0

https://www.zacks.com/stock/news/2244951/merck-s-mrk-keytruda-lynparza-combo-fails-2nd-lung-cancer-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2244951 Mar 22, 2024 - Merck's attempt to use the Keytruda-Lynparza combination in certain non-small cell lung cancer patients has come up short with a second pivotal study failure. 0